Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS ) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

Discover why Hims & Hers Health's subscriber growth, profitability, and telehealth expansion make it a strong buy with a ...

Investors who lost money in Hims & Hers (NYSE: HIMS) are being urged to actively participate in a securities class action lawsuit.

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Most investors have noticed that most stocks in the healthcare sector have declined to levels not seen in a while, making ...

U.S. News compares companies to their industry peers based on a variety of company fundamentals, performance metrics and investor preferences to help you find the right stocks for your investing style ...

Josh Nathan-Kazis is a senior writer at Barron's, covering the healthcare industry. He is a former staff writer at the Forward, where he investigated nonprofits, covered local and national politics, ...

The healthcare outsourcing market is expanding rapidly worldwide, and the Philippines, with more than 200,000 remote professionals, is playing a key role ...

Hims & Hers Health, Inc. (NYSE: HIMS) is one of the best Russell 2000 stocks to buy now. On August 18, Truist Securities ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, ...